Septerna (NASDAQ:SEPN) Stock Rating Lowered by Wall Street Zen

Key Points

• Septerna has been downgraded by Wall Street Zen from a "hold" to a "sell" rating, reflecting growing concerns about its financial performance.
• The company reported earnings of ($0.56) per share, significantly missing analysts' estimates of ($0.05), and had revenue of only $0.12 million compared to expectations of $22.50 million.
• Despite the downgrade, Septerna still holds an average rating of "Moderate Buy" from analysts, with an average price target of $26.75.

Septerna (NASDAQ:SEPN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald increased their price objective on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. HC Wainwright initiated coverage on Septerna in a research report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price objective on the stock. Finally, Wells Fargo & Company increased their price objective on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Septerna currently has a consensus rating of "Moderate Buy" and an average price target of $26.75.

Septerna Price Performance

Shares of NASDAQ:SEPN traded up $0.16 during trading on Friday, hitting $11.09. 164,622 shares of the company were exchanged, compared to its average volume of 239,568. The company has a market cap of $494.39 million and a PE ratio of -1.10. The stock has a 50 day moving average of $11.58 and a 200 day moving average of $9.09. Septerna has a 52-week low of $4.17 and a 52-week high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million during the quarter, compared to analysts' expectations of $22.50 million. Sell-side analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SEPN. JPMorgan Chase & Co. bought a new position in Septerna in the fourth quarter valued at $871,000. Geode Capital Management LLC bought a new position in Septerna in the fourth quarter valued at $8,717,000. Wells Fargo & Company MN bought a new position in Septerna in the fourth quarter valued at $244,000. Invesco Ltd. bought a new position in Septerna in the fourth quarter valued at $278,000. Finally, Legal & General Group Plc bought a new position in Septerna in the fourth quarter valued at $42,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.